Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints

OBJECTIVES: We report the in vitro activity of amikacin and comparators against Gram-negative bacteria collected from blood and respiratory specimens in China during a 1-year period between December 2015 and December 2016. MATERIALS AND METHODS: Minimum inhibitory concentrations (MICs) were determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuti, Joseph L, Wang, Qi, Chen, Hongbin, Li, Henan, Wang, Hui, Nicolau, David P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975598/
https://www.ncbi.nlm.nih.gov/pubmed/29872328
http://dx.doi.org/10.2147/IDR.S161636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975598/
https://www.ncbi.nlm.nih.gov/pubmed/29872328
http://dx.doi.org/10.2147/IDR.S161636

Ejemplares similares